Downgrades Overweight Eq-Weight X

IMCR Immunocore

Morgan Stanley

$74 $35

Downgrades Outperform Neutral X

IMCR Immunocore

Mizuho

$72 $38

Initiated Sell X

IMCR Immunocore

UBS

$24

Downgrades Buy Neutral X

IMCR Immunocore

Guggenheim

Initiated Outperform X

IMCR Immunocore

Leerink Partners

$74

Resumed Overweight X

IMCR Immunocore

JP Morgan

$60

Initiated Overweight X

IMCR Immunocore

Cantor Fitzgerald

Initiated Outperform X

IMCR Immunocore

Robert W. Baird

$84

Upgrades Neutral Overweight X

IMCR Immunocore

JP Morgan

$9 $22

Initiated Buy X

IMCR Immunocore

Needham

$75

Initiated Overweight X

IMCR Immunocore

CapitalOne

$84

Initiated Hold X

IMCR Immunocore

Canaccord Genuity

$67

Initiated Buy X

IMCR Immunocore

Mizuho

$70

Initiated Buy X

IMCR Immunocore

Guggenheim

$85

Initiated Buy X

IMCR Immunocore

Bryan Garnier

$16

Upgrades Neutral Buy X

IMCR Immunocore

Goldman

$33 $80

Initiated Overweight X

IMCR Immunocore

Barclays

$80

Initiated Overweight X

IMCR Immunocore

Morgan Stanley

$77

Initiated Buy X

IMCR Immunocore

Ladenburg Thalmann

$82

Initiated Outperform X

IMCR Immunocore

Cowen

$70

Initiated Buy X

IMCR Immunocore

BTIG Research

$85

Initiated Buy X

IMCR Immunocore

H.C. Wainwright

$80

Initiated Outperform X

IMCR Immunocore

Oppenheimer

$56

Initiated Neutral X

IMCR Immunocore

Goldman

$40

Initiated Buy X

IMCR Immunocore

Jefferies

$65

Initiated Overweight X

IMCR Immunocore

JP Morgan

$58

IMCR  Immunocore Holdings Limited

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.